OS Therapies Completes Requalification Of Phase 2b Herlystic Drug Substance For Confirmatory Phase 3 Trial
Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K's MHRA for Early Commercial Access and Trial Authorisation
Share
Why It Matters
OS Therapies finished checking its cancer drug Herlystic for safety. Now it can ask the U.K. for permission to use it sooner.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.